Identification and characterization of degradation products of irbesartan using LC-MS/TOF, MSn, on-line H/D exchange and LC-NMR

Journal of Pharmaceutical and Biomedical Analysis

Volumn 51, Issue 5, 2010, Pages 1037-1046

  Shah, Ravi P ^a   Sahu, Archana ^a   Singh, Saranjit ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Degradation products; Irbesartan; LC MS TOF; LC NMR; On line H D exchange

Indexed keywords

1 [1 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHANAMINE]PENTYLIDENEAMINO]CYCLOPENTATE CARBOXYLIC ACID; 2 BUTYL 3 (TETRAZOLO[1,5 F]PHENANTHRIDIN 6 YLMETHYL) 1,3 DIAZASPIRO[4,4]NON 1 EN 4 ONE; 2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL METHANAMINE; DRUG METABOLITE; IRBESARTAN; UNCLASSIFIED DRUG;

ARTICLE; DEUTERIUM HYDROGEN EXCHANGE; DRUG DEGRADATION; DRUG DETERMINATION; DRUG STABILITY; DRUG STRUCTURE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; TIME OF FLIGHT MASS SPECTROMETRY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; CHROMATOGRAPHY, LIQUID; DEUTERIUM EXCHANGE MEASUREMENT; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MODELS, CHEMICAL; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PHOTOLYSIS; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; TETRAZOLES;

EID: 72749098773     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.11.008     Document Type: Article

References (21)

1. ICH. Stability testing of new drug substances and products Q1A(R2). International Conference on Harmonisation (2003), IFPMA, Geneva
2. WHO. Draft Stability Testing of Active Pharmaceutical Ingredients and Pharmaceutical Products (2007), World Health Organization, Geneva
3. CPMP. Note for Guidance on Stability Testing: Stability Testing of Existing Active Substances and Related Finished Products (2002), Committee for Proprietary Medicinal Products, EMEA, London
4. TPD. Guidance for Industry Stability Testing of Existing Drug Substances and Products (2003), Therapeutic Products Directorate, Health Canada, Ottawa, ON
5. Bakshi M., and Singh S. Development of validated stability-indicating assay methods-critical review. J. Pharm. Biomed. Anal. 28 (2002) 1011-1040
6. Görög S. The importance and the challenges of impurity profiling in modern pharmaceutical analysis. TrAC 25 (2006) 755-757
7. Murakami T., Kawasaki T., Takemura A., Fukutsu N., Kishi N., and Kusu F. Identification of degradation products in loxoprofen sodium adhesive tapes by liquid chromatography-mass spectrometry and dynamic pressurized liquid extraction-solid-phase extraction coupled to liquid chromatography-nuclear magnetic resonance spectroscopy. J. Chromatogr. A 1208 (2008) 164-174
8. Novak P., Tepes P., Ilijas M., Fistric I., Bratos I., Avdagic A., Hamersak Z., Markovic V.G., and Dumic M. LC-NMR and LC-MS identification of an impurity in a novel antifungal drug icofungipen. J. Pharm. Biomed. Anal. 50 (2009) 68-72
9. Murakami T., Fukutsu N., Kondo J., and Kawasaki T. Application of liquid chromatography-two-dimensional nuclear magnetic resonance spectroscopy using pre-concentration column trapping and liquid chromatography-mass spectrometry for the identification of degradation products in stressed commercial amlodipine maleate tablets. J. Chromatogr. A 1181 (2008) 67-76
10. Dev R.V., Kiran G.S.U., Subbaiah B.V., Babu B.S., Babu J.M., Dubey P.K., and Vyas K. Identification of degradation products in stressed tablets of rabeprazole sodium by HPLC-hyphenated techniques. Magn. Reson. Chem. 47 (2009) 443-448
11. Shah R.P., Kumar V., and Singh S. Liquid chromatography/mass spectrometric studies on atorvastatin and its stress degradation products. Rapid Commun. Mass Spectrom. 22 (2008) 613-622
12. Powell J.R., Reeves R.A., Marino M.R., Cazaubon C., and Nisato D. A review of the new angiotensin II-receptor antagonist irbesartan. Cardiovasc. Drug Rev. 16 (1998) 169-194
13. Morales-Olivas F.J., Aristegui I., Estan L., Rodicio J.L., Moreno A., Gil V., Ferrón G., and Velasco O. The KARTAN study: a postmarketing assessment of irbesartan in patients with hypertension. Clin. Ther. 26 (2004) 232-244
14. Mbah C.J. Kinetics of decomposition of irbesartan in aqueous solutions determined by high performance liquid chromatography. Pharmazie 59 (2004) 920-922
15. Hillaert S., DeBeer T.R.M., DeBeer J.O., and Bossche W.V. Optimization and validation of a micellar electrokinetic chromatographic method for the analysis of several angiotensin-II-receptor antagonists. J. Chromatogr. A 984 (2003) 135-146
16. Wang G., Fiske J.D., Jennings S.P., Tomasella F.P., Palaniswamy V.A., and Ray K.L. Identification and control of a degradation product in Avapro™ film-coated tablet: low dose formulation. Pharm. Dev. Technol. 13 (2008) 393-399
17. ICH. Stability testing: photostability testing of new drug substances and products Q1B. International Conference on Harmonisation (1996), IFPMA, Geneva
18. Seburg R.A., Ballard J.M., Hwang T., and Sullivan C.M. Photosensitized degradation of losartan potassium in an extemporaneous suspension formulation. J. Pharm. Biomed. Anal. 42 (2006) 411-422
19. March J. Advanced Organic Chemistry, Reactions, Mechanisms and Structure. 4th ed. (2005), John Wiley and Sons, Singapore pp. 384
20. March J. Advanced Organic Chemistry, Reactions, Mechanisms and Structure. 4th ed. (2005), John Wiley and Sons, Singapore pp. 885
21. Moore D.E. In: Tonnesen H. (Ed). The Photostability of Drugs and Drug Formulations (1996), Taylor and Francis, London 85